Enhanced erythropoiesis and iron metabolism

1. A method of treating anemia in a human subject comprising administering to the human subject an effective amount of a compound, wherein the human subject has a transferrin saturation (TSAT) level below 20% prior to said administering and wherein the compound is a compound of Formula I

wherein

A is —CR 5 R 6 and R 5 and R 6 are each hydrogen;

B is —CO 2 H;

X is O;

Q is O;

R 4 is hydrogen

Y is CR 3 ;

R 1 , R 2 and R 3 are identical or different and are hydrogen, hydroxyl, halogen, cyano, trifluoromethyl, nitro, carboxyl, (C 1 -C 20 )-alkyl, (C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )cycloalkyl-(C 1 -C 12 )-alkyl, (C 3 -C 8 )-cycloalkoxy, (C 3 -C 8 )-cycloalkyl-(C 1 -C 12 )-alkoxy, (C 3 -C 8 )-cycloalkyloxy-(C 1 -C 12 )-alkyl, (C 3 -C 8 )-cycloalkyloxy-(C 1 -C 12 )-alkoxy, (C 3 -C 8 )-cycloalkyl-(C 1 -C 8 )-alkyl-(C 1 -C 6 )-alkoxy, (C 3 -C 8 )-cycloalkyl-(C 1 -C 8 )-alkoxy-(C 1 -C 6 )-alkyl, (C 3 -C 8 )-cycloalkyloxy-(C 1 -C 8 )-alkoxy-(C 1 -C 6 )-alkyl, (C 3 -C 8 )-cycloalkoxy-(C 1 -C 8 )-alkoxy-(C 1 -C 8 )-alkoxy, (C 6 -C 2 )-aryl, (C 7 -C 16 )-aralkyl, (C 7 -C 16 )-aralkenyl, (C 7 -C 16 )-aralkynyl, (C 2 -C 20 )-alkenyl, (C 2 -C 20 )-alkynyl, (C 1 -C 20 )-alkoxy, (C 2 -C 20 )-alkenyloxy, (C 2 -C 20 )-alkynyloxy, retinyloxy, (C 1 -C 20 )-alkoxy-(C 1 -C 12 )-alkyl, (C 1 -C 12 )-alkoxy-(C 1 -C 12 )-alkoxy, (C 1 -C 12 )-alkoxy-(C 1 -C 8 )-alkoxy-(C 1 -C 8 )-alkyl, (C 6 -C 12 )-aryloxy, (C 7 -C 16 )-aralkyloxy, (C 6 -C 12 )-aryloxy-(C 1 -C 6 )-alkoxy, (C 7 -C 16 )-aralkoxy-(C 1 -C 6 )-alkoxy, (C 1 -C 16 )-hydroxyalkyl, (C 6 -C 16 )-aryloxy-(C 1 -C 8 )-alkyl, (C 7 -C 16 )-aralkoxy-(C 1 -C 8 )-alkyl, (C 6 -C 12 )-aryloxy-(C 1 -C 8 )-alkoxy-(C 1 -C 6 )-alkyl, (C 7 -C 12 )-aralkyloxy-(C 1 -C 8 )-alkoxy-(C 1 -C 6 )-alkyl, (C 2 -C 20 )-alkenyloxy-(C 1 -C 6 )-alkyl, (C 2 -C 20 )-alkynyloxy-(C 1 -C 6 )-alkyl, retinyloxy-(C 1 -C 6 )-alkyl, —O—[CH 2 ] x CfH (2f+1−g) F g , —OCF 2 Cl, —OCF 2 —CHFCl, (C 1 -C 20 )-alkylcarbonyl, (C 3 -C 8 )-cycloalkylcarbonyl, (C 6 -C 12 )-arylcarbonyl, (C 7 -C 16 )-aralkylcarbonyl, cinnamoyl, (C 2 -C 20 )-alkenylcarbonyl, (C 2 -C 20 )-alkynylcarbonyl, (C 1 -C 20 )-alkoxycarbonyl, (C 1 -C 12 )-alkoxy-(C 1 -C 12 )-alkoxycarbonyl, (C 6 -C 12 )-aryloxycarbonyl, (C 7 -C 16 )-aralkoxycarbonyl, (C 3 -C 8 )-cycloalkoxycarbonyl, (C 2 -C 20 )-alkenyloxycarbonyl, retinyloxycarbonyl, (C 2 -C 20 )-alkynyloxycarbonyl, (C 6 -C 12 )-aryloxy-(C 1 -C 6 )-alkoxycarbonyl, (C 7 -C 16 )-aralkoxy-(C 1 -C 6 )-alkoxycarbonyl, (C 3 -C 8 )-cycloalkyl-(C 1 -C 6 )-alkoxycarbonyl, (C 3 -C 8 )-cycloalkoxy-(C 1 -C 6 )-alkoxycarbonyl, (C 1 -C 12 )-alkylcarbonyloxy, (C 3 -C 8 )-cycloalkylcarbonyloxy, (C 6 -C 12 )-arylcarbonyloxy, (C 7 -C 16 )-aralkylcarbonyloxy, cinnamoyloxy, (C 2 -C 12 )-alkenylcarbonyloxy, (C 2 -C 12 )-alkynylcarbonyloxy, (C 1 -C 12 )-alkoxycarbonyloxy, (C 1 -C 2 )-alkoxy-(C 1 -C 12 )-alkoxycarbonyloxy, (C 6 -C 12 )-aryloxycarbonyloxy, (C 7 -C 16 )-aralkyloxycarbonyloxy, (C 3 -C 8 )-cycloalkoxycarbonyloxy, (C 2 -C 12 )-alkenyloxycarbonyloxy, (C 2 -C 12 )-alkynyloxycarbonyloxy, carbamoyl, N—(C 1 -C 12 )-alkylcarbamoyl, N,N-di-(C 1 -C 12 )-alkylcarbamoyl, N—(C 3 -C 8 )-cycloalkylcarbamoyl, N,N-dicyclo-(C 3 -C 8 )-alkylcarbamoyl, N—(C 1 -C 10 )-alkyl-N—(C 3 -C 8 )-cycloalkylcarbamoyl, N—((C 3 -C 8 )-cycloalkyl-(C 1 -C 6 )-alkyl)-carbamoyl, N—(C 1 -C 6 )-alkyl-N—((C 3 -C 8 )-cycloalkyl-(C 1 -C 6 )-alkyl)-carbamoyl, N-(+)-dehydroabietylcarbamoyl, N—(C 1 -C 6 )-alkyl-N-(+)-dehydroabietylcarbamoyl, N—(C 6 -C 12 )-arylcarbamoyl, N—(C 7 -C 16 )-aralkylcarbamoyl, N—(C 1 -C 10 )-alkyl-N—(C 6 -C 16 )-arylcarbamoyl, N—(C 1 -C 10 )-alkyl-N—(C 7 -C 16 )-aralkylcarbamoyl, N—((C 1 -C 18 )-alkoxy-(C 1 -C 10 )-alkyl)-carbamoyl, N—((C 6 -C 16 )-aryloxy-(C 1 -C 10 )-alkyl)-carbamoyl, N—((C 7 -C 16 )-aralkyloxy-(C 1 -C 10 )-alkyl)-carbamoyl, N—(C 1 -C 10 )-alkyl-N—((C 1 -C 10 )-alkoxy-(C 1 -C 10 )-alkyl)-carbamoyl, N—(C 1 -C 10 )-alkyl-N—((C 6 -C 12 )-aryloxy-(C 1 -C 10 )-alkyl)-carbamoyl, N—(C 1 -C 10 )-alkyl-N—((C 7 -C 16 )-aralkyloxy-(C 1 -C 10 )-alkyl)-carbamoyl; CON(CH 2 ) h , in which a CH 2 group can be replaced by O, S, N—(C 1 -C 8 )-alkylimino, N—(C 3 -C 8 )-cycloalkylimino, N—(C 3 -C 8 )-cycloalkyl-(C 1 -C 4 )-alkylimino, N—(C 6 -C 12 )-arylimino, N—(C 7 -C 16 )-aralkylimino, N—(C 1 -C 4 )-alkoxy-(C 1 -C 6 )-alkylimino, and h is from 3 to 7; a carbamoyl radical of the formula R

in which

R x and R v are each independently selected from hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 7 )-cycloalkyl, aryl, or the substituent of an α-carbon of an α-amino acid, to which the L- and D-amino acids belong,

s is 1-5,

T is OH, or NR*R**, and R*, R** and R*** are identical or different and are selected from hydrogen, (C 6 -C 12 )-aryl, (C 7 -C 11 )-aralkyl, (C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkyl, (+)-dehydroabietyl, (C 1 -C 8 )-alkoxy-(C 1 -C 8 )-alkyl, (C 7 -C 12 )-aralkoxy-(C 1 -C 8 )-alkyl, (C 6 -C 12 )-aryloxy-(C 1 -C 8 )-alkyl, (C 1 -C 10 )-alkanoyl, optionally substituted (C 7 -C 16 )-aralkanoyl, optionally substituted (C 6 -C 12 )-aroyl; or R* and R** together are —[CH 2 ] h , in which a CH 2 group can be replaced by O, S, SO, SO 2 , N-acylamino, N—(C 1 -C 10 )-alkoxycarbonylimino, N—(C 1 -C 8 )-alkylimino, N—(C 3 -C 8 )-cycloalkylimino, N—(C 3 -C 8 )-cycloalkyl-(C 1 -C 4 )-alkylimino, N—(C 6 -C 12 )-arylimino, N—(C 7 -C 16 )-aralkylimino, N—(C 1 -C 4 )-alkoxy-(C 1 -C 6 )-alkylimino, and h is from 3 to 7;

carbamoyloxy, N—(C 1 -C 12 )-alkylcarbamoyloxy, N,N-di-(C 1 -C 12 )-alkylcarbamoyloxy, N—(C 3 -C 8 )-cycloalkylcarbamoyloxy, N—(C 6 -C 12 )-arylcarbamoyloxy, N—(C 7 -c 16 )-aralkylcarbamoyloxy, N—(C 1 -C 10 )-alkyl-N—(C 6 -C 12 )-arylcarbamoyloxy, N—(C 1 -C 10 )-alkyl-N—(C 7 -C 16 )-aralkylcarbamoyloxy, N—((C 1 -C 10 )-alkyl)-carbamoyloxy, N—((C 6 -C 12 )-aryloxy-(C 1 -C 10 )-alkyl)-carbamoyloxy, N—((C 7 -C 16 )-aralkyloxy-(C 1 -C 10 )-alkyl)-carbamoyloxy, N—(C 1 -C 10 )-alkyl-N—((C 1 -C 10 )-alkoxy-(C 1 -C 10 )-alkyl)-carbamoyloxy, N—(C 1 -C 10 )-alkyl-N—((C 6 -C 12 )-aryloxy-(C 1 -C 10 )-alkyl)-carbamoyloxy, N—(C 1 -C 10 )-alkyl-N—((C 7 -C 16 )-aralkyloxy-(C 1 -C 10 )-alkyl)-carbamoyloxyamino, (C 1 -C 12 )-alkylamino, di-(C 1 -C 12 )-alkylamino, (C 3 -C 8 )-cycloalkylamino, (C 3 -C 12 )-alkenylamino, (C 3 -C 12 )-alkynylamino, N—(C 6 -C 12 )-arylamino, N—(C 7 -C 11 )-aralkylamino, N-alkyl-aralkylamino, N-alkyl-arylamino, (C 1 -C 12 )-alkoxyamino, (C 1 -C 12 )-alkoxy-N—(C 1 -C 10 )-alkylamino, (C 1 -C 12 )-alkanoylamino, (C 3 -C 8 )-cycloalkanoylamino, (C 6 -C 12 )-aroylamino, (C 7 -C 16 )-aralkanoylamino, (C 1 -C 12 )-alkanoyl-N—(C 1 -C 10 )-alkylamino, (C 3 -C 8 )-cycloalkanoyl-N—(C 1 -C 10 )-alkylamino, (C 6 -C 12 )-aroyl-N—(C 1 -C 10 )-alkylamino, (C 7 -C 11 )-aralkanoyl-N—(C 1 -C 10 )-alkylamino, (C 1 -C 12 )-alkanoylamino-(C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkanoylamino-(C 1 -C 8 )-alkyl, (C 6 -C 12 )-aroylamino-(C 1 -C 8 )-alkyl, (C 7 -C 16 )-aralkanoylamino-(C 1 -C 8 )-alkyl, amino-(C 1 -C 10 )-alkyl, N—(C 1 -C 10 )-alkylamino-(C 1 -C 10 )-alkyl, N,N-di(C 1 -C 10 )-alkylamino-(C 1 -C 10 )-alkyl, (C 3 -C 8 )-cycloalkylamino(C 1 -C 10 )-alkyl, (C 1 -C 20 )-alkylmercapto, (C 1 -C 20 )-alkylsulfinyl, (C 1 -C 20 )-alkylsulfonyl, (C 6 -C 12 )-arylmercapto, (C 6 -C 12 )-arylsulfinyl, (C 6 -C 12 )-arylsulfonyl, (C 7 -C 16 )-aralkylmercapto, (C 7 -C 16 )-aralkylsulfinyl, (C 7 -C 16 )-aralkylsulfonyl, (C 1 -C 12 )-alkylmercapto-(C 1 -C 6 )-alkyl, (C 1 -C 12 )-alkylsulfinyl-(C 1 -C 6 )-alkyl, (C 1 -C 12 )-alkylsulfonyl-(C 1 -C 6 )-alkyl, (C 6 -C 12 )-arylmercapto-(C 1 -C 6 )-alkyl, (C 6 -C 12 )-arylsulfinyl-(C 1 -C 6 )-alkyl, (C 6 -C 12 )-arylsulfonyl-(C 1 -C 6 )-alkyl, (C 7 -C 16 )-aralkylmercapto-(C 1 -C 6 )-alkyl, (C 7 -C 16 )-aralkylsulfinyl-(C 1 -C 6 )-alkyl, (C 7 -C 16 )-aralkylsulfonyl-(C 1 -C 6 )-alkyl, sulfamoyl, N—(C 1 -C 10 )-alkylsulfamoyl, N,N-di-(C 1 -C 10 )-alkylsulfamoyl, (C 3 -C 8 )-cycloalkylsulfamoyl, N—(C 6 -C 12 )-arylsulfamoyl, N—(C 7 -C 16 )-aralkylsulfamoyl, N—(C 1 -C 10 )-alkyl-N—(C 6 -C 12 )-arylsulfamoyl, N—(C 1 -C 10 )-alkyl-N—(C 7 -C 16 )-aralkylsulfamoyl, (C 1 -C 10 )-alkylsulfonamido, N—((C 1 -C 10 )-alkyl)-(C 1 -C 10 )-alkylsulfonamido, (C 7 -C 16 )-aralkylsulfonamido, and N—((C 1 -C 10 )-alkyl-(C 7 -C 16 )-aralkylsulfonamido; where an aryl radical may be substituted by 1 to 5 substituents selected from hydroxyl, halogen, cyano, trifluoromethyl, nitro, carboxyl, (C 2 -C 16 )-alkyl, (C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkyl-(C 1 -C 12 )-alkyl, (C 3 -C 8 )-cycloalkoxy, (C 3 -C 8 )-cycloalkyl-(C 1 -C 12 )-alkoxy, (C 3 -C 8 )-cycloalkyloxy-(C 1 -C 12 )-alkyl, (C 3 -C 8 )-cycloalkyloxy-(C 1 -C 12 )-alkoxy, (C 3 -C 8 )-cycloalkyl-(C 1 -C 8 )-alkyl-(C 1 -C 6 )-alkoxy, (C 3 -C 8 )-cycloalkyl(C 1 -C 8 )-alkoxy-(C 1 -C 6 )-alkyl, (C 3 -C 8 )-cycloalkyloxy-(C 1 -C 8 )-alkoxy-(C 1 -C 6 )-alkyl, (C 3 -C 8 )-cycloalkoxy-(C 1 -C 8 )-alkoxy-(C 1 -C 8 )-alkoxy, (C 6 -C 12 )-aryl, (C 7 -C 16 )-aralkyl, (C 2 -C 16 )-alkenyl, (C 2 -C 12 )-alkynyl, (C 1 -C 16 )-alkoxy, (C 1 -C 16 )-alkenyloxy, (C 1 -C 12 )-alkoxy-(C 1 -C 12 )-alkyl, (C 1 -C 12 )-alkoxy-(C 1 -C 12 )-alkoxy, (C 1 -C 12 )-alkoxy(C 1 -C 8 )-alkoxy-(C 1 -C 8 )-alkyl, (C 6 -C 12 )-aryloxy, (C 7 -C 16 )-aralkyloxy, (C 6 -C 12 )-aryloxy-(C 1 -C 6 )-alkoxy, (C 7 -C 16 )-aralkoxy-(C 1 -C 6 )-alkoxy, (C 1 -C 8 )-hydroxyalkyl, (C 6 -C 16 )-aryloxy-(C 1 -C 8 )-alkyl, (C 7 -C 16 )-aralkoxy-(C 1 -C 8 )-alkyl, (C 6 -C 12 )-aryloxy-(C 1 -C 8 )-alkoxy-(C 1 -C 6 )-alkyl, (C 7 -C 12 )-aralkyloxy-(C 1 -C 8 )-alkoxy-(C 1 -C 6 )-alkyl, —O—[CH 2 ] x C f H (2f+1−g) F g , —OCF 2 Cl, —OCF 2 —CHFCl, (C 1 -C 12 )-alkylcarbonyl, (C 3 -C 8 )- cycloalkylcarbonyl, (C 6 -C 12 )-arylcarbonyl, (C 7 -C 16 )-aralkylcarbonyl, (C 1 -C 12 )-alkoxycarbonyl, (C 1 -C 12 )-alkoxy-(C 1 -C 12 )-alkoxycarbonyl, (C 6 -C 12 )-aryloxycarbonyl, (C 7 -C 16 )-aralkoxycarbonyl, (C 3 -C 8 )-cycloalkoxycarbonyl, (C 2 -C 12 )-alkenyloxycarbonyl, (C 2 -C 12 )-alkynyloxycarbonyl, (C 6 -C 12 )-aryloxy-(C 1 -C 6 )-alkoxycarbonyl, (C 7 -C 16 )-aralkoxy-(C 1 -C 6 )-alkoxycarbonyl, (C 3 -C 8 )-cycloalkyl-(C 1 -C 6 )-alkoxycarbonyl, (C 3 -C 8 )-cycloalkoxy-(C 1 -C 6 )-alkoxycarbonyl, (C 1 -C 12 )-alkylcarbonyloxy, (C 3 -C 8 )-cycloalkylcarbonyloxy, (C 6 -C 12 )-arylcarbonyloxy, (C 7 -C 16 )-aralkylcarbonyloxy, cinnamoyloxy, (C 2 -C 12 )-alkenylcarbonyloxy, (C 2 -C 12 )-alkynylcarbonyloxy, (C 1 -C 12 )-alkoxycarbonyloxy, (C 1 -C 12 )-alkoxy-(C 1 -C 12 )-alkoxycarbonyloxy, (C 6 -C 12 )-aryloxycarbonyloxy, (C 7 -C 16 )-aralkyloxycarbonyloxy, (C 3 -C 8 )-cycloalkoxycarbonyloxy, (C 2 -C 12 )-alkenyloxycarbonyloxy, (C 2 -C 12 )-alkynyloxycarbonyloxy, carbamoyl, N—(C 1 -C 12 )-alkylcarbamoyl, N,N-di(C 1 -C 12 )-alkylcarbamoyl, N—(C 3 -C 8 )-cycloalkylcarbamoyl, N,N-dicyclo-(C 3 -C 8 )-alkylcarbamoyl, N—(C 1 -C 10 )-alkyl-N—(C 3 -C 8 )-cycloalkylcarbamoyl, N—((C 3 -C 8 )-cycloalkyl-(C 1 -C 6 )-alkyl)carbamoyl, N—(C 1 -C 6 )-alkyl-N—((C 3 -C 8 )-cycloalkyl-(C 1 -C 6 )-alkyl)carbamoyl, N-(+)-dehydroabietylcarbamoyl, N—(C 1 -C 6 )-alkyl-N-(+)-dehydroabietylcarbamoyl, N—(C 6 -C 12 )-arylcarbamoyl, N—(C 7 -C 16 )-aralkylcarbamoyl, N—(C 1 -C 10 )-alkyl-N—(C 6 -C 16 )-arylcarbamoyl, N—(C 1 -C 10 )-alkyl-N—(C 7 -C 16 )-aralkylcarbamoyl, N—((C 1 -C 16 )-alkoxy-(C 1 -C 10 )-alkyl)carbamoyl, N—((C 6 -C 16 )-aryloxy-(C 1 -C 10 )-alkyl)carbamoyl, N—((C 7 -C 16 )-aralkyloxy-(C 1 -C 10 )-alkyl)carbamoyl, N—(C 1 -C 10 )-alkyl-N—((C 1 -C 10 )-alkoxy-(C 1 -C 10 )-alkyl)carbamoyl, N—(C 1 -C 10 )-alkyl-N—((C 6 -C 12 )-aryloxy-(C 1 -C 10 )-alkyl)carbamoyl, N—(C 1 -C 10 )-alkyl-N—((C 7 -C 16 )-aralkyloxy-(C 1 -C 10 )-alkyl)-carbamoyl, CON(CH 2 ) h , in which a CH 2 group can be replaced by, O, S, N—(C 1 -C 8 )-alkylimino, N—(C 3 -C 8 )-cycloalkylimino, N—(C 3 -C 8 )-cycloalkyl-(C 1 -C 4 )-alkylimino, N—(C 6 -C 12 )-arylimino, N—(C 7 -C 16 )-aralkylimino, N—(C 1 -C 4 )-alkoxy-(C 1 -C 6 )-alkylimino, and h is from 3 to 7; carbamoyloxy, N—(C 1 -C 12 )-alkylcarbamoyloxy, N,N-di-(C 1 -C 12 )-alkylcarbamoyloxy, N—(C 3 -C 8 )-cycloalkylcarbamoyloxy, N—(C 6 -C 16 )-arylcarbamoyloxy, N—(C 7 -C 16 )-aralkylcarbamoyloxy, N—(C 1 -C 10 )-alkyl-N—(C 6 -C 12 )-arylcarbamoyloxy, N—(C 1 -C 10 )-alkyl-N—(C 7 -C 16 )-aralkylcarbamoyloxy, N—((C 1 -C 10 )-alkyl)carbamoyloxy, N—((C 6 -C 12 )-aryloxy-(C 1 -C 10 )-alkyl)carbamoyloxy, N—((C 7 -C 16 )-aralkyloxy-(C 1 -C 10 )-alkyl)carbamoyloxy, N—(C 1 -C 10 )-alkyl-N—((C 1 -C 10 )-alkoxy-(C 1 -C 10 )-alkyl)carbamoyloxy, N—(C 1 -C 10 )-alkyl-N—((C 6 -C 12 )-aryloxy-(C 1 -C 10 )-alkyl)carbamoyloxy, N—(C 1 -C 10 )-alkyl-N—((C 7 -C 16 )-aralkyloxy-(C 1 -C 10 )-alkyl)carbamoyloxy, amino, (C 1 -C 12 )-alkylamino, di-(C 1 -C 12 )-alkylamino, (C 3 -C 8 )-cycloalkylamino, (C 3 -C 12 )-alkenylamino, (C 3 -C 12 )-alkynylamino, N—(C 6 -C 12 )-arylamino, N—(C 7 -C 11 )-aralkylamino, N-alkyl-aralkylamino, N-alkyl-arylamino, (C 1 -C 12 )-alkoxyamino, (C 1 -C 12 )-alkoxy-N—(C 1 -C 10 )-alkylamino, (C 1 -C 12 )-alkanoylamino, (C 3 -C 8 )-cycloalkanoylamino, (C 6 -C 12 )-aroylamino, (C 7 -C 16 )-aralkanoylamino, (C 1 -C 12 )-alkanoyl-N—(C 1 -C 10 )-alkylamino, (C 3 -C 8 )-cycloalkanoyl-N—(C 1 -C 10 )-alkylamino, (C 6 -C 12 )-aroyl-N—(C 1 -C 10 )-alkylamino, (C 7 -C 11 )-aralkanoyl-N—(C 1 -C 10 )-alkylamino, (C 1 -C 12 )-alkanoylamino-(C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkanoylamino-(C 1 -C 8 )-alkyl, (C 6 -C 12 )-aroylamino-(C 1 -C 8 )-alkyl, (C 7 -C 16 )-aralkanoylamino-(C 1 -C 8 )-alkyl, amino-(C 1 -C 10 )-alkyl, N—(C 1 -C 10 )-alkylamino-(C 1 -C 10 )-alkyl, N,N-di-(C 1 -C 10 )-alkylamino-(C 1 -C 10 )-alkyl, (C 3 -C 8 )-cycloalkylamino-(C 1 -C 10 )-alkyl, (C 1 -C 12 )-alkylmercapto, (C 1 -C 12 )-alkylsulfinyl, (C 1 -C 12 )-alkylsulfonyl, (C 6 -C 16 )-arylmercapto, (C 6 -C 16 )-arylsulfinyl, (C 6 -C 16 )-arylsulfonyl, (C 7 -C 16 )-aralkylmercapto, (C 7 -C 16 )-aralkylsulfinyl, or (C 7 -C 16 )-aralkylsulfonyl;

including the physiologically active salts derived therefrom.

2. The method of claim 1 , wherein the compound inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase enzyme activity.

3. A method of treating anemia in a human subject comprising administering to the human subject an effective amount of a compound, wherein the human subject has a transferrin saturation (TSAT) level below 20% prior to said administering and wherein the compound is a compound of Formula I

wherein

A is —CR 5 R 6 and R 5 and R 6 are each hydrogen;

B is —CO 2 H;

X is O;

Q is O;

Y is CR 3

R 1 , R 2 and R 3 are identical or different and are hydrogen, halogen, (C 1 -C 20 )-alkyl, (C 6 -C 12 )-aryl, (C 1 -C 20 )-alkoxy, (C 6 -C 12 )-aryloxy, N—((C 1 -C 18 )-alkoxy-(C 1 -C 10 )-alkyl)-carbamoyl, (C 6 -C 12 )-arylmercapto; where an aryl radical may be substituted by 1 to 5 substituents selected from halogen;

including the physiologically active salts derived therefrom.

4. The method of claim 3 , wherein the compound inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase enzyme activity.

5. The method of claim 1 , wherein the compound is orally administered to the human subject.

6. The method of claim 1 , wherein the erythropoietin plasma level in the human subject is increased following administration of the effective amount of the compound.

7. The method of claim 1 , wherein the iron level in the human subject is increased following administration of the effective amount of the compounds.

8. The method of claim 1 , wherein the human subject has a transferrin saturation level below 16%, below 15%, or below 10%.

9. The method of claim 1 , wherein the method increases the transferrin saturation level in the subject to a level above 20%, above 30%, above 40%, or above 50%.

10. The method of claim 1 , wherein the anemia does not respond to treatment with exogenously administered erythropoietin.

11. The method of claim 1 , wherein the percent transferrin saturation in the human subject is increased to a value between 25% to 50% following administration of the effective amount of the compound.

12. The method of claim 1 , wherein the hemoglobin level in the human subject is increased following administration of the effective amount of the compound.

13. The method of claim 1 , wherein the human subject is a subject having iron deficiency.

14. The method of claim 13 , wherein the human subject is a subject having a functional iron deficiency.

15. The method of claim 3 , wherein the compound is orally administered to the human subject.

16. The method of claim 3 , wherein the erythropoietin plasma level in the human subject is increased following administration of the effective amount of the compound.

17. The method of claim 3 , wherein the iron level in the human subject is increased following administration of the effective amount of the compounds.

18. The method of claim 3 , wherein the human subject has a transferrin saturation level below 16%, below 15%, or below 10%.

19. The method of claim 3 , wherein the method increases the transferrin saturation level in the human subject to a level above 20%, above 30%, above 40%, or above 50%.

20. The method of claim 3 , wherein the anemia does not respond to treatment with exogenously administered erythropoietin.

21. The method of claim 3 , wherein the percent transferrin saturation in the human subject is increased to a value between 25% to 50% following administration of the effective amount of the compound.

22. The method of claim 3 , wherein the hemoglobin level in the human subject is increased following administration of the effective amount of the compound.

23. The method of claim 3 , wherein the human subject is a subject having iron deficiency.

24. The method of claim 23 , wherein the human subject is a subject having a functional iron deficiency.